Compare Annaly Capital Management, Inc. (NLY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs 10X Genomics Inc — how do they compare? Annaly Capital Management, Inc. trades at $22.83 (market cap $17.12B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: Annaly Capital Management, Inc. is far larger — about 2× 10X Genomics Inc's market cap, and Annaly Capital Management, Inc. pays a 13.2% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| NLY | TXG | |
|---|---|---|
Market Cap | $17.12B | $8.55B |
Sector | Financials | Health |
52-Week High | $24.40 | $67.29 |
52-Week Low | $20.21 | $11.34 |
Dividend Yield | 13.2% | — |
Enterprise Value | — | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $22.72, down 0.39% today, with a technical bearish signal but strong fundamentals including a P/E of 5.49 and ROE of 20.66%. Recent earnings beats and a $0.75 dividend highlight operational strength, though cash flow volatility and high leverage pose risks.
Outlook remains positive with analyst consensus at Buy (57% of 28 analysts) and a $24.33 price target, offering ~7% upside. Key risks include interest rate sensitivity and debt levels, but diversified mortgage assets and consistent dividend coverage support income appeal.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
